As reported by Agence France-Presse, Didier Jambart claims he used up his family's savings and resorted to stealing after becoming addicted to Internet gambling, and that he also became sexually compulsive, engaging in cross-dressing, exposing himself online and participating in risky sexual encounters that culminated in being raped.

Jambart stopped taking Requip in 2005. His lawyers maintain that a warning about effects like those their client allegedly suffered did not appear on a product package insert until 2006.

Patient information currently listed on Glaxo's website (pdf) says: "Some patients taking REQUIP get urges to behave in a way unusual for them. Examples of this are an unusual urge to gamble or increased sexual urges and behaviors. If you notice or your family notices that you are developing any unusual behaviors, talk to your healthcare provider."

Requip isn't the only Glaxo drug on lawyers' minds these days. The company reported last month that it expects to take a $3.4 billion legal charge for the fourth quarter of 2010; the figure stems largely from legal costs involving its Avandia diabetes drug, which plaintiffs allege causes heart problems.

As reported by Agence France-Presse, Didier Jambart claims he used up his family's savings and resorted to stealing after becoming addicted to Internet gambling, and that he also became sexually compulsive, engaging in cross-dressing, exposing himself online and participating in risky sexual encounters that culminated in being raped.

Jambart stopped taking Requip in 2005. His lawyers maintain that a warning about effects like those their client allegedly suffered did not appear on a product package insert until 2006.

Patient information currently listed on Glaxo's website (pdf) says: "Some patients taking REQUIP get urges to behave in a way unusual for them. Examples of this are an unusual urge to gamble or increased sexual urges and behaviors. If you notice or your family notices that you are developing any unusual behaviors, talk to your healthcare provider."

Requip isn't the only Glaxo drug on lawyers' minds these days. The company reported last month that it expects to take a $3.4 billion legal charge for the fourth quarter of 2010; the figure stems largely from legal costs involving its Avandia diabetes drug, which plaintiffs allege causes heart problems.